The equity plan amendment (Proposal Three) is the most consequential item — if approved, it authorizes a potentially large evergreen share pool that could lead to significant dilution. The activist SC 13D/A filing by director Ogawa suggests possible dissident activity; monitor for any proxy contest or withhold-vote campaign ahead of the November 5 meeting. The performance milestones for RSUs (Nasdaq listing + $10M revenue/funding by end of 2027) provide a concrete catalyst timeline.
Price Chart
Executive Summary
Palomino Laboratories Inc. filed its definitive proxy statement for the 2026 Annual Meeting, seeking shareholder approval for the re-election of all three incumbent directors, ratification of KNAV CPA LLP as auditor, and a significant amendment to the 2025 Equity Incentive Plan to increase the share reserve to the greater of 10 million shares or 15% of outstanding common stock. The filing follows a recent SC 13D/A by activist Richard Ogawa (also a director and Secretary), signaling potential governance tension. The proxy reveals extensive related-party transactions involving the CEO's and director's family members, no board committees, and performance-based RSUs tied to a $10M revenue/orders or $40M funding milestone and a Nasdaq/NYSE listing by end of 2027.
Key Facts
- Annual Meeting scheduled for November 5, 2026; record date September 23, 2026 with 27,636,539 shares outstanding.
- Proposal Three seeks to amend the 2025 Equity Incentive Plan to reserve the greater of 10,000,000 shares or 15% of outstanding common stock for issuance.
- CEO Jeffrey Shealy holds 17.3% beneficial ownership; all directors and executive officers as a group hold 30.3%.
- Lucius Partners LLC owns 14.5% and Karthik Gopalakrishnan owns 7.2% — both 5%+ holders.
- Extensive related-party transactions: CEO's wife (Erica Honick) received 62,500 restricted shares and $10,000/month consulting; CEO's brother, father-in-law, sister, and director's wife also received restricted stock or consulting fees.
- Board has no committees; only one director (Steven DenBaars) is considered independent under Nasdaq standards.
- Performance-based RSUs granted to CEO (900,000), CAO (100,000), and directors (200,000 each) vest only upon achieving $10M orders/payments or $40M funding AND listing on Nasdaq/NYSE by Dec 31, 2027.
- Recent SC 13D/A filed by director Richard Ogawa (48 days ago) — potential activist context for the proxy vote.
- Auditor KNAV CPA LLP earned $197,950 in total fees for FY2025.
- No say-on-pay vote or shareholder proposals on the ballot.
Financial Impact
Equity plan amendment could increase dilution by up to ~15% of outstanding shares (4.1M+ shares at current 27.6M outstanding). CEO annual salary $300,000; CAO consulting $10,000/month. Related-party consulting arrangements total $20,000/month to CEO's wife and director's wife.
Risk Factors
- Potential shareholder dissent on equity plan amendment due to dilution concerns (15% of outstanding shares).
- Activist director Ogawa's SC 13D/A could signal a proxy fight or board challenge.
- Extensive related-party transactions raise governance red flags and could attract negative attention from institutional investors.
- No board committees and only one independent director — weak governance structure.
- Performance milestones for RSUs are binary and may not be achieved, potentially demotivating management.
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEF 14A Filing (Primary) | 0001493152-26-046296 |
| Document: 0001493152-26-046296-index-headers.html | 0001493152-26-046296 |
| Document: 0001493152-26-046296-index.html | 0001493152-26-046296 |
| Document: 0001493152-26-046296.txt | 0001493152-26-046296 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 8-K/A | $14.32 | awaiting T+60 | — | $14.01 (−2.16%) |
Oct 8, 2026 18d ago | DEF 14A | $16.00 | awaiting T+60 | — | $14.01 (−12.44%) |
Jul 16, 2026 14w ago | 8-K | $7.35 $14.01 | ▲ +90.61% | ▲ +86.64% | $14.01 (+90.61%) |
May 5, 2026 24w ago | 8-K | — | awaiting T+60 | — | — |
Apr 24, 2026 26w ago | 8-K | — | awaiting T+60 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers